uniQure(NASDAQ) QURE

uniQure N.V. builds treatments for people with rare diseases. These medicines fix genetic problems to stop or slow illness. One dose can provide health benefits for years.

Medicines for Rare Genetic Conditions

• HEMGENIX: Treatment for hemophilia B that helps patients produce clotting factor IX; generates license revenues via a partnership with CSL Behring.
• AMT-130: Investigational gene therapy for Huntington’s disease currently in Phase I/II clinical trials to evaluate safety and effectiveness.
• AMT-260: Gene therapy candidate for patients with a form of epilepsy that is difficult to treat with standard medications.
• AMT-191: Treatment candidate for Fabry disease designed to restore enzyme activity that is missing in affected patients.
• AMT-162: Clinical-stage candidate for patients with a specific form of amyotrophic lateral sclerosis, which is a progressive nervous system disease.

Strategic Steps and New Capital

• In June 2026, the company raised $242.7 million in net proceeds through a follow-on public offering of 5.7 million ordinary shares.
• The company amended its $175 million loan facility with Hercules Capital in July 2026 to extend the period for drawing down additional funds.
• In 2024, the firm divested its commercial manufacturing operations to Genezen to focus resources on research and pipeline development.
• The company reached alignment with the Food and Drug Administration in July 2026 on a pathway for an accelerated Biologics License Application submission.

A Focus on Gene Silencing

uniQure uses its proprietary platform to design treatments that silence toxic genes in the brain. The company operates specialized research centers in both the Netherlands and the United States.

Recent Performance by the Numbers

• License revenues were $5.8 million in the three months ended June 30, 2026.
• Net loss was $134.6 million in the six months ended June 30, 2026, compared to a net loss of $81.4 million in the prior year period.
• Cash, cash equivalents, and investment securities totaled $810.3 million as of June 30, 2026.
• Selling, general, and administrative expenses reached $37.4 million in the six months ended June 30, 2026, up from $24.4 million year over year.
• Research and development expenses were $63.1 million in the six months ended June 30, 2026.

The Path to Commercialization

uniQure has transitioned from a manufacturing-heavy firm to a focused gene therapy developer with a deep clinical pipeline. Its progress depends on successfully navigating the regulatory process for its lead genetic candidates.